Key Takeaways (4-6 bullets, will render as highlighted box)
- The 2025 Eli Lilly Zepbound Savings Card reduced commercially insured patients' copay to as low as $25 per fill, with annual benefit caps.
- LillyDirect launched single-dose vial pricing in 2024, offering Zepbound at about $349 to $499 per month for self-paying patients (depending on dose), bypassing pen pricing.
- Government-insured patients (Medicare, Medicaid, TRICARE, VA) were excluded from the savings card in 2025 by federal law and remain excluded in 2026.
- Many 2025 program terms carry forward into 2026 with adjustments. Always check the current terms on Eli Lilly's site before relying on a saved version.
- For patients without commercial coverage, compounded tirzepatide through licensed telehealth platforms remained the most affordable monthly option in 2025 and 2026.
Direct answer (40-60 words)
The 2025 Zepbound coupon, officially the Eli Lilly Zepbound Savings Card, reduced commercially insured patients' copay to as little as $25 per fill (with caps). Lilly also offered direct cash-pay pricing through LillyDirect at $349 to $499 per month for single-dose vials. Both programs continue in 2026 with adjusted terms. Government-insured patients remain excluded from the savings card.
Table of contents
- The 30-second answer
- The Zepbound Savings Card in 2025
- LillyDirect: the 2024-2025 cash-pay vial program
- Who qualified, who didn't
- Real-world savings: example scenarios
- What changed for 2026
- Compounded tirzepatide as the affordability alternative
- How to verify current 2026 program terms
- FAQ
- Sources
- Footer disclaimers
The Zepbound Savings Card in 2025
Eli Lilly launched the Zepbound Savings Card alongside the Zepbound product introduction in late 2023. By 2025, the program had two main tiers, depending on whether your commercial plan covered Zepbound.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Tier 1: Commercial plan covers Zepbound.
- Savings card reduced copay to as little as $25 per fill
- Annual benefit cap: about $1,800 per year (varied by program version)
- Maximum 12 months of use per patient before re-enrollment
- Worked for any FDA-approved Zepbound dose (2.5, 5, 7.5, 10, 12.5, 15 mg)
Tier 2: Commercial plan does not cover Zepbound.
- Savings card reduced cost to about $550 per month for the pen
- Equivalent to a partial cash-pay rebate
- Annual benefit cap (capped per fill and yearly)
- Worked for the same dose range
The 2025 version was meaningful for patients whose insurance covered Zepbound but with high copays (e.g., $300 specialty tier copays dropped to $25). It was less helpful for patients whose plans didn't cover Zepbound at all.
LillyDirect: the 2024-2025 cash-pay vial program
In August 2024, Eli Lilly launched a direct-to-consumer program called LillyDirect that sold Zepbound in single-dose vials (rather than the standard auto-injector pens) at lower cash prices. The vial format was the same molecule, dose-equivalent, but in a different delivery format.
LillyDirect 2025 vial pricing:
| Dose | Approximate cash price (1 month, 4 vials) |
|---|---|
| 2.5 mg | $349 |
| 5 mg | $499 |
| 7.5 mg | $499 (limited availability) |
| 10 mg | $499 (limited availability) |
How LillyDirect worked:
- Patient enrolled at LillyDirect.com
- Provided prescription information from their prescribing clinician
- Chose vial dose
- Paid direct online
- Vials shipped from a Lilly-partner pharmacy
Key features:
- Required a valid Zepbound prescription from a U.S.-licensed clinician
- Could not be combined with insurance
- Could not be combined with the savings card
- Vial format requires patient to draw the dose with a syringe
The strategic point of LillyDirect: The program was Lilly's response to the surge in compounded tirzepatide demand during the 2023-2024 tirzepatide shortage. By offering direct cash-pay vials at $349 to $499, Lilly competed with the cash-pay compounded market while keeping the brand-name Zepbound auto-injector pens at higher list prices for the insured-patient market.
Who qualified, who didn't
Savings Card eligibility (2025):
- 18 years or older
- U.S. resident
- Commercial (private, employer, or marketplace) prescription drug coverage, OR no coverage that includes Zepbound (for the Tier 2 cash-equivalent rate)
- Valid Zepbound prescription
- Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program
- Not a resident of states with restrictions on copay assistance (Massachusetts and California had restrictions on certain plans)
LillyDirect cash-pay eligibility:
- 18 years or older
- U.S. resident
- Valid Zepbound prescription
- Self-paying (no insurance involvement)
- Not subject to state restrictions
Excluded from both programs:
- Anyone using Medicare or Medicaid (federal law)
- Anyone using TRICARE or VA
- Patients in states where the program was restricted (changed by state)
The exclusion of government-insured patients is a federal Anti-Kickback Statute restriction, not an Eli Lilly choice. Manufacturer copay assistance and patient cash-pay programs that operate outside of insurance generally cannot include patients whose drugs are paid by federal programs (HHS OIG advisory opinions on copay assistance).
Real-world savings: example scenarios
Scenario 1: Commercial PPO with Zepbound on Tier 3.
- Patient: BMI 32, no diabetes, employer PPO with $300 specialty copay for Zepbound
- Savings card: brought copay to $25 per fill
- Monthly cost: $25
- Annual savings: about $3,300
Scenario 2: High-deductible plan, deductible not met.
- Patient: BMI 30, healthcare exchange high-deductible plan, $4,000 deductible unmet
- Pre-deductible cost at pharmacy: $1,300
- Savings card brought cost down to: about $1,025 (capped reduction)
- Monthly cost until deductible met: still expensive
Scenario 3: Commercial plan does not cover Zepbound.
- Patient: BMI 31, commercial plan excludes weight-loss medications
- Savings card Tier 2: brought cost to about $550 per month
- LillyDirect vial program: $349 (2.5 mg) or $499 (5+ mg) per month
- Monthly cost: $349 to $550 depending on path chosen
Scenario 4: Medicare patient.
- Patient: BMI 33, Medicare Part D plan
- Savings card: not allowed
- LillyDirect: not allowed (the program was designed to bypass insurance, but the federal law applies regardless)
- Monthly cost: full Part D specialty tier ($300 to $500)
Scenario 5: Uninsured patient.
- Patient: BMI 32, no insurance
- Savings card Tier 2: brought cost to about $550
- LillyDirect: $349 to $499
- Monthly cost: $349 (lowest legitimate option for brand-name)
The pattern across scenarios: the 2025 programs worked best for commercially insured patients with high copays. They were modestly helpful for uninsured patients (LillyDirect was the better path). They didn't help government-insured patients at all.
What changed for 2026
Eli Lilly updates program terms annually, sometimes mid-year. As of April 2026, the major changes from 2025 include:
Savings Card 2026:
- Tier 1 (covered) copay floor: still as low as $25 per fill
- Tier 2 (not covered) effective rate: adjusted slightly upward
- Annual benefit cap: rebalanced
- Some state restrictions changed
LillyDirect 2026:
- Single-dose vial program continues
- 2.5 mg and 5 mg pricing largely held
- Higher doses (7.5, 10, 12.5, 15 mg) entered vial program in expanded form
- Prescriber and pharmacy network broadened
New for 2026:
- Eli Lilly indicated possible Medicare Part D coverage expansion under new federal guidance for obesity medications (CMS guidance, late 2025)
- Some commercial plans dropped Zepbound from formulary, others added it
- More employers added GLP-1 coverage as a benefit
The practical implication: A 2025 Zepbound coupon screenshot saved on your phone is probably out of date. Always verify the current program terms at LillyDirect.com or Zepbound.lilly.com before relying on past pricing.
Compounded tirzepatide as the affordability alternative
Throughout 2025, compounded tirzepatide remained the most affordable monthly option for patients without commercial coverage of Zepbound, at $179 to $379 per month through licensed telehealth platforms.
Important context on compounded tirzepatide in 2024-2025:
- The FDA placed tirzepatide on the official drug shortage list in late 2022
- During the shortage, 503A and 503B compounding pharmacies were permitted to compound tirzepatide
- The FDA removed tirzepatide from the shortage list in October 2024
- After removal, compounding restrictions returned (compounding for individualized clinical needs only, not for "office stock" or convenience)
As of 2026:
- Compounded tirzepatide remains available for patients with documented individual clinical need
- Standard compounding (without medical justification beyond cost) is no longer permitted under FDA rules
- Patient access depends on the prescriber documenting the medical need
For patients who have a documented clinical reason that brand-name Zepbound cannot meet (clinically required dose customization, allergy to a brand inactive ingredient, FDA-listed shortage period), compounded tirzepatide is a path. For patients seeking compounding solely for affordability outside of a documented shortage, the path is more limited under current FDA guidance.
This is an evolving area. The FormBlends Medical Team reviews each request individually and follows current FDA guidance on compounding rules.
How to verify current 2026 program terms
Step 1: Go to LillyDirect.com or Zepbound.lilly.com directly. Don't rely on third-party sites or screenshots.
Step 2: Look for the "savings card" or "savings program" link. Read the current terms (effective dates, eligibility, benefit caps).
Step 3: Call the LillyDirect customer service line printed on the program page.
Step 4: Cross-check with your insurance plan. Even if the savings card looks generous, your insurance has to cover Zepbound for the card to reduce a copay.
Step 5: If shopping the cash-pay program, confirm your prescriber will route the prescription correctly through LillyDirect (which uses specific Lilly-partner pharmacies).
Step 6: For state-specific restrictions, check the savings card terms for the state-by-state list. California, Massachusetts, and a few others have had restrictions on copay assistance for certain plan types.
A screenshot of program terms is only as accurate as its date. Manufacturers update terms quarterly or more often. The two-minute verification on Lilly's actual site protects you from showing up at the pharmacy with an expired program.
Internal links
- For Zepbound vs. Wegovy comparison, see /articles/comparison/zepbound-vs-wegovy/
- For Zepbound side effects and dosing, see /articles/side-effects/zepbound-side-effects/
- For overall GLP-1 cost guidance, see /articles/cost-and-insurance/
FAQ
Was there a Zepbound coupon for 2025? Yes. Eli Lilly's Zepbound Savings Card reduced commercially insured patients' copay to as little as $25 per fill in 2025. There was also a separate Tier 2 rate of about $550/month for patients whose commercial plan did not cover Zepbound. LillyDirect's vial cash-pay program offered $349 to $499 per month.
Is the Zepbound savings card still active in 2026? Yes, in updated form. The Tier 1 floor (covered copay reduced to $25) continues. Other terms (annual caps, eligibility) have been adjusted. Always verify current terms at Zepbound.lilly.com or LillyDirect.com before counting on a specific number.
Can Medicare patients use the Zepbound coupon? No. Federal law prohibits manufacturer copay coupons and direct cash-pay programs that bypass insurance from including Medicare, Medicaid, TRICARE, or VA patients. This was true in 2025 and remains true in 2026.
What is LillyDirect? LillyDirect is Eli Lilly's direct-to-consumer cash-pay program that launched in 2024. It sells Zepbound in single-dose vials at $349 (2.5 mg) to $499 (5 mg and higher) per month. Patients enroll online and receive vials by mail. The program continues in 2026 with expanded dose availability.
How is the Zepbound vial different from the pen? The active ingredient is the same (tirzepatide). The vial requires drawing the dose into a syringe before injecting; the pen is pre-filled and auto-injects with the click of a button. Vials are cheaper because they have lower production and packaging costs. Some patients find pens easier; others don't mind the vial.
Can I combine the savings card with LillyDirect? No. The savings card works through retail pharmacy with insurance. LillyDirect is a cash-pay direct program with no insurance. They are mutually exclusive paths. Pick the one that gives you the lower out-of-pocket cost.
Does the savings card cover the Zepbound vial? The savings card was designed for the Zepbound auto-injector pen sold through retail pharmacies. The LillyDirect vial program has its own pricing structure and doesn't use the savings card. Check current Zepbound.lilly.com terms for any vial-specific savings programs.
What if my insurance doesn't cover Zepbound at all? Options: request a formulary exception with medical necessity documentation, use the Tier 2 savings card rate (about $550/month in 2025), use LillyDirect cash-pay vials ($349 to $499/month), explore compounded tirzepatide if you have documented clinical justification, or consider switching to a covered GLP-1.
Are there income-based assistance programs for Zepbound? Eli Lilly offers patient assistance through LillyCares for some Lilly products. As of early 2026, Zepbound was on a different track than other Lilly drugs in the assistance program structure. Income-eligible patients should check LillyCares.org and confirm with a Lilly representative whether Zepbound is currently included.
Will Medicare cover Zepbound in 2026? As of April 2026, Medicare Part D coverage for Zepbound is limited and depends on indication and plan. CMS guidance issued in late 2025 opened the door to broader coverage of obesity medications under Part D, but plan-by-plan implementation varies. Check your specific Part D plan's formulary for current coverage.
Where do I find the most accurate 2026 Zepbound coupon information? Go directly to Zepbound.lilly.com (Eli Lilly's official Zepbound site) or LillyDirect.com. Avoid third-party sites that may show outdated screenshots. Manufacturer terms update quarterly or more often. Calling the LillyDirect customer service line is the fastest way to confirm current pricing for your specific situation.
What about compounded tirzepatide as an alternative? Compounded tirzepatide was widely available during the 2022-2024 tirzepatide shortage. After the FDA removed tirzepatide from the shortage list in October 2024, compounding restrictions returned. Patients with documented individual clinical need can still access compounded tirzepatide through licensed telehealth platforms like FormBlends, with monthly costs typically $179 to $379.
Sources
- Eli Lilly and Company. Zepbound Savings Card terms. 2025 program documents.
- Eli Lilly and Company. LillyDirect direct-to-consumer cash-pay program. Launched August 2024, updated 2025-2026.
- U.S. Food and Drug Administration. Tirzepatide drug shortage status update. October 2024.
- U.S. Department of Health and Human Services, Office of Inspector General. Advisory opinions on manufacturer copay assistance programs.
- Federal Anti-Kickback Statute. 42 U.S.C. § 1320a-7b(b).
- Centers for Medicare and Medicaid Services. Part D coverage guidance for obesity medications. 2025.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
- Eli Lilly and Company. Zepbound prescribing information. Revised 2024-2025.
- U.S. Food and Drug Administration. Compounding under sections 503A and 503B of the FD&C Act. Guidance documents. 2024-2025.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound, Mounjaro, and LillyDirect are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. TRICARE and Medicare are programs administered by the U.S. government. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →